EP1567154A4
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
Abstract
This record has no abstract on file.
Term
Term ended
Projected expiry passed 6 November 2023, 2.9 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
34 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13 Sheet 14 Sheet 15 Sheet 16 Sheet 17 Sheet 18 Sheet 19 Sheet 20 Sheet 21 Sheet 22 Sheet 23 Sheet 24 Sheet 25 Sheet 26 Sheet 27 Sheet 28 Sheet 29 Sheet 30 Sheet 31 Sheet 32 Sheet 33 Sheet 34
Every citation, both waysCites: the store holds 6 of 7
| Document | Relation | Office | Category | Cited during | Relevant claims |
|---|---|---|---|---|---|
| WO0134606A1 | Cites | World Intellectual Property Organization (WIPO) | – | Examiner | – |
| WO03086373A1 | Cites | World Intellectual Property Organization (WIPO) | XP | Search report | 1-30 |
| US5698579A | Cites | United States of America | XD | Search report | 1-14,16-30 |
| WO9906041A1 | Cites | World Intellectual Property Organization (WIPO) | XD | Search report | 1-9,15-30 |
| WO03086373A | Cites | World Intellectual Property Organization (WIPO) | – | – | – |
| WO9906041A | Cites | World Intellectual Property Organization (WIPO) | – | – | – |
| MARRIOTT J B ET AL: "Immunotherapeutic and antitumour potential of thalidomide analogues.", EXPERT OPINION ON BIOLOGICAL THERAPY. JUL 2001, vol. 1, no. 4, July 2001 (2001-07-01), pages 675 - 682, XP009062910, ISSN: 1471-2598 | Non-patent | – | – | Search report | – |
| HIDESHIMA TERU ET AL: "Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy", BLOOD, vol. 96, no. 9, 1 November 2000 (2000-11-01), pages 2943 - 2950, XP002371346, ISSN: 0006-4971 | Non-patent | – | – | Search report | – |
| DATABASE NLDB [online] XP002371400, retrieved from STN Database accession no. 2002:87776 | Non-patent | – | – | Search report | – |
| DATABASE PHIN [online] "Celgene moving beyond Thalidomid", XP002371401, retrieved from STN Database accession no. 2001:12958 | Non-patent | – | – | Search report | – |
| LI ET AL: "Tumor angiogenesis: Molecular pathology, therapeutic targeting, and imaging", ACADEMIC RADIOLOGY, RESTON, VA, US, vol. 7, no. 10, October 2000 (2000-10-01), pages 800 - 811, XP005262256, ISSN: 1076-6332 | Non-patent | – | – | Search report | – |
| OLIVER S J ET AL: "Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 118, no. 2, November 1999 (1999-11-01), pages 315 - 321, XP002371347, ISSN: 0009-9104 | Non-patent | – | – | Search report | – |
539 members in 41 offices
Priority claims9
| Document | Office | Kind | Date |
|---|---|---|---|
| 424601P | United States of America | – | |
| 42460102 | United States of America | P | |
| 42460102 | United States of America | P | |
| 0335545 | United States of America | W | |
| 0335545 | United States of America | W | |
| 424601P | – | – | – |
| US20020424601P | – | – | – |
| US2003035545 | – | – | – |
| WO2003US35545 | – | – | – |
Members539
| Document | Office | Kind | |
|---|---|---|---|
| CA2476983A1 | Canada | A1 | |
| CA2486141A1 | Canada | A1 | |
| CA2672000A1 | Canada | A1 | |
| CA2727824A1 | Canada | A1 | |
| CA2727830A1 | Canada | A1 | |
| CA2752122A1 | Canada | A1 | |
| CA2752124A1 | Canada | A1 | |
| CA2752127A1 | Canada | A1 | |
| CA2752140A1 | Canada | A1 | |
| CA2794060A1 | Canada | A1 | |
| CA2794297A1 | Canada | A1 | |
| CA2855306A1 | Canada | A1 | |
| CA2855359A1 | Canada | A1 | |
| WO03097040A1 | World Intellectual Property Organization (WIPO) | A1 | |
| WO03097052A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU2003234624A1 | Australia | A1 | |
| AU2003234626A1 | Australia | A1 | |
| AU2003234626C1 | Australia | C1 | |
| WO03097052A3 | World Intellectual Property Organization (WIPO) | A3 | |
| US2004029832A1 | United States of America | A1 | |
| CA2505128A1 | Canada | A1 | |
| CA2505131A1 | Canada | A1 | |
| WO2004043377A2 | World Intellectual Property Organization (WIPO) | A2 | |
| WO2004043378A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU2003290651A1 | Australia | A1 | |
| AU2003290652A1 | Australia | A1 | |
| WO2004043377A3 | World Intellectual Property Organization (WIPO) | A3 | |
| WO2004043378A3 | World Intellectual Property Organization (WIPO) | A3 | |
| AU2004240548A1 | Australia | A1 | |
| CA2525557A1 | Canada | A1 | |
| WO2004103274A2 | World Intellectual Property Organization (WIPO) | A2 | |
| TW200500355A | Taiwan Province of China | A | |
| TW200501945A | Taiwan Province of China | A | |
| KR20050010812A | Republic of Korea | A | |
| KR20050010815A | Republic of Korea | A | |
| NO20055976L | Norway | L | |
| MXPA04011310A | Mexico | A | |
| MXPA04011311A | Mexico | A | |
| EP1505973A2 | European Patent Office (EPO) | A2 | |
| WO2004103274A3 | World Intellectual Property Organization (WIPO) | A3 | |
| AU2004270211A1 | Australia | A1 | |
| CA2537092A1 | Canada | A1 | |
| CA2687924A1 | Canada | A1 | |
| CA2687927A1 | Canada | A1 | |
| CA2688694A1 | Canada | A1 | |
| CA2688695A1 | Canada | A1 | |
| CA2688708A1 | Canada | A1 | |
| CA2688709A1 | Canada | A1 | |
| CA2741412A1 | Canada | A1 | |
| CA2741575A1 | Canada | A1 | |
| WO2005023192A2 | World Intellectual Property Organization (WIPO) | A2 | |
| US2005096351A1 | United States of America | A1 | |
| KR20050072801A | Republic of Korea | A | |
| KR20050072802A | Republic of Korea | A | |
| EP1556033A1 | European Patent Office (EPO) | A1 | |
| MXPA05004734A | Mexico | A | |
| US2005176681A1 | United States of America | A1 | |
| HK1072180A1 | Hong Kong, China | A1 | |
| EP1567154A2 | European Patent Office (EPO) | A2 | |
| EP1567158A2 | European Patent Office (EPO) | A2 | |
| BR0316050A | Brazil | A | |
| CN1668296A | China | A | |
| BR0316057A | Brazil | A | |
| WO2005023192A3 | World Intellectual Property Organization (WIPO) | A3 | |
| MXPA05004780A | Mexico | A | |
| JP2005530780A | Japan | A | |
| JP2005530784A | Japan | A | |
| US2005234017A1 | United States of America | A1 | |
| IS8127A | Iceland | A | |
| CN1697655A | China | A | |
| IL165254D0 | Israel | D0 | |
| IL165258A0 | Israel | A0 | |
| IL165258D0 | Israel | D0 | |
| KR20060012618A | Republic of Korea | A | |
| US2006030594A1 | United States of America | A1 | |
| CN1735412A | China | A | |
| CN1735415A | China | A | |
| US2006035955A1 | United States of America | A1 | |
| MXPA05012155A | Mexico | A | |
| IS8340A | Iceland | A | |
| AU2003234626B2 | Australia | B2 | |
| JP2006508131A | Japan | A | |
| AR047994A1 | Argentina | A1 | |
| EP1635826A2 | European Patent Office (EPO) | A2 | |
| CR8146A | Costa Rica | A | |
| US2006069065A1 | United States of America | A1 | |
| IL171960A0 | Israel | A0 | |
| IL171960D0 | Israel | D0 | |
| PE20060284A1 | Peru | A1 | |
| AP2006003558A0 | African Regional Intellectual Property Organization (ARIPO) | A0 | |
| JP2006514689A | Japan | A | |
| EP1505973A4 | European Patent Office (EPO) | A4 | |
| EP1567158A4 | European Patent Office (EPO) | A4 | |
| US2006105993A1 | United States of America | A1 | |
| BRPI0410306A | Brazil | A | |
| EP1556033A4 | European Patent Office (EPO) | A4 | |
| EP1567154A4This record | European Patent Office (EPO) | A4 | |
| MXPA06001994A | Mexico | A | |
| ZA200409388B | South Africa | B | |
| NO20061528L | Norway | L |
Showing 100 of 539
24 legal events, as the office reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | |
|---|---|---|
| Application deemed to be withdrawnWithdrawn18D | 18D | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWNSTAA | STAA | |
| First examination report despatched17Q | 17Q | |
| Party data changed (applicant data changed or rights of an application transferred)RAP1 | RAP1 | |
| Supplementary search report drawn up and despatchedA4 | A4 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Information provided on ipc code assigned before grantRIC1 | RIC1 | |
| Requested extension states of the european patent have changedRAX | RAX | |
| Requested extension states of the european patent have changedRAX | RAX | |
| Requested extension states of the european patent have changedRAX | RAX | |
| Requested extension states of the european patent have changedRAX | RAX | |
| Request for examination filed17P | 17P | |
| Designated contracting statesAK | AK | |
| Request for extension of the european patentAX | AX | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI |
Numbers
- Publication
- 1567154
- Publication, DOCDB
- 1567154
- Publication, EPODOC
- EP1567154
- Application
- 3783234
- Application, DOCDB
- 03783234
- Application, EPODOC
- EP20030783234
Titles3
- German
- VERFAHREN UNDZUSAMMENSETZUNGEN MIT SELEKTIVEN CYTOKIN-HEMMENDEN ARZNEIMITTELN ZURBEHANDLUNG UND VERSORGUNG VON KREBS UND ANDEREN ERKRANKUNGEN
- English
- METHODS AND COMPOSITIONS USING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
- French
- PROCEDES ET COMPOSITIONS UTILISANT DES MEDICAMENTS D'INHIBITION SELECTIVE DE CYTOKINE POUR TRAITER ET MAITRISER DES CANCERS ET D'AUTRES MALADIES
Classification
- CPC, 20
- A61K31/40
- A61K31/44
- A61K31/00
- A61K31/4035
- A61K31/415
- A61K31/425
- A61K31/454
- A61K31/522
- A61K38/1816
- A61K38/193
- A61K38/2013
- A61K38/21
- A61K45/06
- A61P1/04
- A61P19/02
- A61P27/02
- A61P27/06
- A61P31/22
- A61P35/00
- A61P43/00
- IPC, 16
- A61K31 00
- A61K31 40
- A61K31 4035
- A61K31 415
- A61K31 425
- A61K31 44
- A61K31 445
- A61K31 454
- A61K31 515
- A61K45 06
- A61P35 00
- A61P27 02
- A61P27 06
- A61P19 02
- A61P1 04
- A61P31 22
Designated states2
- Contracting states, 1
- Türkiye
- Extension states, 1
- North Macedonia